Immuno-virological and Clinical Follow-up of Persons With HIV-2 (PWHIV-2) Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate (BIC/FTC/TAF): A Retrospective Study.

IF 8.2 1区医学 Q1 IMMUNOLOGY

Clinical Infectious Diseases Pub Date : 2025-03-17 DOI:10.1093/cid/ciae447

Véronique Joly, Valentine M Ferré, Quentin Le Hingrat, Gilles Peytavin, Mélanie Cresta, Charlotte Charpentier, Marc Digumber, Florence Damond, Yazdan Yazdanpanah, Sophie Matheron, Diane Descamps, Jade Ghosn

引用次数: 0

Abstract

This retrospective study evaluated Bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafenamide (TAF) in 24 persons with human immunodeficiency virus type 2 (HIV-2, PWHIV-2), 5 naive and 19 pretreated. After a median follow-up of 37.5 months, all PWHIV-2 had a plasma viral load <40 copies/mL. Median CD4 count increased significantly from 580 to 625 cells/mm3, suggesting the effectiveness of BIC/FTC/TAF to treat HIV-2 infection.

查看原文本刊更多论文

接受比特拉韦/恩曲他滨/富马酸替诺福韦阿拉非酰胺（BIC/FTC/TAF）治疗的 HIV-2 感染者（PWHIV-2）的免疫-病毒学和临床随访：回顾性研究。

这项回顾性研究评估了 Bictegravir/FTC/TAF 在 24 名 PWHIV（5 名新感染者和 19 名预处理者）中的疗效。中位随访 37.5 个月后，所有 PWHIV-2 的血浆病毒载量均小于 40 拷贝/毫升。CD4 细胞计数中位数从 580 个/立方毫米大幅增至 625 个/立方毫米，这表明比特拉韦/四氯化碳/他汀类药物对治疗 HIV-2 感染非常有效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Infectious Diseases 医学-传染病学

CiteScore

25.00

自引率

2.50%

发文量

900

审稿时长

3 months

期刊介绍： Clinical Infectious Diseases (CID) is dedicated to publishing original research, reviews, guidelines, and perspectives with the potential to reshape clinical practice, providing clinicians with valuable insights for patient care. CID comprehensively addresses the clinical presentation, diagnosis, treatment, and prevention of a wide spectrum of infectious diseases. The journal places a high priority on the assessment of current and innovative treatments, microbiology, immunology, and policies, ensuring relevance to patient care in its commitment to advancing the field of infectious diseases.